Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study was designed to analyze the prognosis and recurrence predictive factors of high
risk patients (Clinical Risk Scoreā„3) of resectable colorectal liver metastasis.
The efficacy of perioperative chemotherapy plus cetuximab and chemotherapy alone was compared
for these patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Beijing Cancer Hospital
Collaborators:
Beijing Municipal Administration of Hospitals The First Affiliated Hospital of Kunming Medical College West China Hospital Zhejiang Cancer Hospital